On June 8, 2018, Genome Medicine published research co-authored by:
• 1997 Glenn/AFAR Scholarship for Research in the Biology of Aging, 2007 Beeson Scholar, and 2015 recipient of the AFAR-administered MetLife Foundation Award for Medical Research in Alzheimer’s Disease, Randall Bateman, M.D.
• AFAR 2013 New Investigator in Alzheimer's Disease recipient Carlos Cruchaga, Ph.D.
• 2017 New Investigator Awards in Alzheimer’s Disease recipient Celeste Karch, Ph.D.
In “Genetic variants associated with Alzheimer’s disease confer different cerebral cortex cell-type population structure,” the researchers conclude “that genetic risk factors associated with AD etiology have a specific imprinting in the cellular composition of AD brains.”
In a related press release from the Washington University School of Medicine in St. Louis, Dr. Cruchaga states: “Many efforts are underway to identify novel Alzheimer’s disease genes… But once a gene is identified, we need to know what it does in the brain to understand how it can lead to disease. We also need to account for the proportions of various types of cells if we want to know what we should target with therapies.”
Read the published research here and a related press release here.
Randall Bateman, M.D., is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine.
Carlos Cruchaga, Ph.D., is an Associate Professor of psychiatry in the Division of Biology and Biomedical Sciences at Washington University in St. Louis.
Celeste Karch, Ph.D., is an Assistant Professor of psychiatry at Washington University School of Medicine in St. Louis.
